antimalarial treatment

The declining effectiveness of the available antimalarial drugs due to drug resistance requires a continued effort to develop new therapeutic approaches. In this context, combination therapies hold a great promise for developing effective first-line antimalarial treatments for reducing malaria mortality. The present study explores the antimalarial efficacy of nanotized formulation of curcumin in combination with benzothiophene compound 6 (3-bromo-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide) with a view to achieve better efficacy at a very low dose in comparison to that accomplished with monotherapy alone.

In “Concomitant bacteremia in adults with severe falciparum malaria” in this issue of Clinical Infectious Diseases, 9 of 845 Southeast Asian adults with severe malaria (1%) had bacteremia upon admission, but 4 of those 9 patients (44%) died compared with 108 of 836 (13%) nonbacteremic patients.